Kidney cancer survival statistics and rates

This page was reviewed under our medical and editorial policy by

Maurie Markman, MD, President, Medicine & Science.

This page was updated on May 20, 2022.

At City of Hope, we understand that you may want to see information regarding the survival results of patients with distant (also referred to as metastatic) kidney cancer who were diagnosed and/or at least initially partly treated at our hospitals to help you and your family decide where to go for treatment, as part of many other factors you may be considering. Therefore, we asked an independent biostatistician to analyze the survival results of City of Hope patients.

Statistical methodology and limitations
Qualifications of the independent researchers

The chart below reflects the City of Hope and SEER survival rates for kidney cancer patients with distant (metastatic) disease who were diagnosed between 2000 and 2015. It includes estimates of the percentage of kidney cancer patients with distant (metastatic) disease who survived for six months to five years after the initial diagnosis, as recorded in the City of Hope and SEER databases.

  • This analysis included kidney cancer patients from City of Hope who had primary tumor sites (as coded by ICD-O-2 (1973+)) of C649, were diagnosed from 2000 to 2015 (including 2000 and 2015) and received at least part of their initial course of treatment at City of Hope. All patients included in the analysis were considered analytic patients by City of Hope.
  • Kidney cancer patients with distant (metastatic) disease from the SEER database and kidney cancer patients with distant (metastatic) disease from the City of Hope database were included in the analysis. In addition, the analysis excluded patients whose medical records were missing any of the following information:

    • SEER Summary Stages
    • Primary tumor sites
    • Cancer histologic types
    • Date of initial diagnosis
    • Age at initial diagnosis
    • Gender
    • Race

kidney cancer survival rate

*The SEER data represent national results over a large number of institutions and have been included for illustrative purposes. They are not intended to represent a controlled study and/or a perfect analysis of the City of Hope data because of variability in the sample sizes of the two databases, the clinical condition(s) of the patients treated, and other factors.

The City of Hope sample is relatively small because only metastatic kidney cancer patients who had been initially diagnosed at City of Hope and/or received at least part of their initial course of treatment at City of Hope were included. These factors significantly reduced the size of the City of Hope sample, which means that the estimates reflected in the survival chart may be subject to high variation and may not be replicated in the future when we have a larger City of Hope sample for analysis.

For a full, technical explanation of the methodology used in the analyses and a detailed description of the City of Hope and SEER patient groups included, click here to view statistical methodology, and for more information about the SEER program, go to seer.cancer.gov.

We also want to be sure you understand that cancer is a complex disease and each person’s medical condition is different; therefore, City of Hope makes no claims about the efficacy of specific treatments, the delivery of care, nor the meaning of the City of Hope and SEER analyses. Not all cancer patients who are treated at a City of Hope hospital may experience these same results.

Next topic: What are the facts about kidney cancer?

Expert cancer care

is one call away.
appointments in as little as 24 hrs.